There is new guidance on the use of popular weight loss medications like Zepbound and Wegovy to help improve heart health.

Dr. Tara Narula takes a look at weight-loss medications and how entire families can benefit when one person starts taking the drugs.

Dr. Alexandra Sowa, an obesity medicine physician and author, explains how these medications affect muscle mass and what you can do to help preserve it.

Dr. Alexandra Sowa, an obesity medicine physician and author, shares what you need to know about reaching your goal while on weight-loss medications.

ABC News' Dr. Tara Narula explains a new study indicating that stopping GLP 1 weight loss medications too soon could make it harder to lose weight.

U.K. regulators issued guidance on Thursday, warning weight loss and diabetes medications may weaken the effectiveness of birth control and may be harmful in pregnancy.

Health regulators say popular weight-loss medications may impact the effectiveness of birth control. ABC News’ Chief Medical Correspondent Dr. Tara Narula has more.

Despite benefits, up to 85% of patients stop using GLP-1 medications after two years.

President Donald Trump signed an executive order on Monday aimed at lowering prescription drug prices in the U.S. Here's what you need to know.

ABC News chief medical correspondent Dr. Tara Narula breaks down what to know about a new study that says Zepbound may be superior than other GLP-1 weight loss medications.

Scientists have been studying other possible health benefits of GLP-1s.

Hims, Ro and LifeMD will soon start selling Wegovy at a reduced price of $499 per month.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

ABC News' Dr. Tara Narula breaks down new research that shows semaglutide may improve inflammation and liver scarring.

The popular weight-loss medication Wegovy will soon be available to telehealth companies. ABC News' Dr. Darien Sutton breaks down the latest.

Dave Moore, senior vice president of U.S. operations at Novo Nordisk, says his company wants to “meet patients where they are.”

Novo Nordisk announced it is making the popular weight loss medication available to three telehealth companies and revealed plans to make it more affordable for those paying out-of-pocket.

Dr. Katherine Saunders, at Weill Cornell Medicine, joined ABC News' to discuss a new daily weight loss pill by Eli Lilly saying it "opens up opportunities" to treat diseases.

Dr. Rekha Kumar, endocrinologist and obesity medicine expert at Weill Cornell Medicine, joined ABC News Live to discuss the promising results from Eli Lilly's newly announced weight loss pill.

New research data shows a new, oral GLP-1 medication can potentially benefit people with Type 2 diabetes.

Drug maker Eli Lilly says data from a late-stage trial showed a reduction in weight of almost 8% in people with Type 2 diabetes.

ABC News' Dr. Darien Sutton discusses the rise of GLP-1 weight loss drugs, when to consider them and their role in long-term weight management.

As GLP-1 drugs become more popular, more celebrities are opening up about their weight loss and wellness journeys.

President Donald Trump's administration says Medicare and Medicaid will not pay for GLP-1 drugs when used for weight loss.

The Trump administration announced that it will not expand coverage for weight loss medication, GLP-1 drugs like Zepbound and Wegovy.

The comedian shares why she changed medications after what she described as a bad experience years ago.

The FBI warns counterfeit versions of weight loss drugs drugs can cause significant health issues.

The FBI is warning about counterfeit weight loss drugs being sold that claim to have semaglutide, the key ingredient in Ozempic and Wegovy.

ABC News' Dr. Tara Narula shares what patients need to know.

ABC News chief medical correspondent Dr. Tara Narula breaks down what patients need to know.

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by antidepressants and obesity medications.

"GMA" explores a New York Times report on the unexpected impact of weight loss medications on relationships.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less alcohol.

The "Hims and Hers" commercial railed against the weight loss industry and promoted the company's weight loss drug offerings as a less costly option compared to brand-name drugs.

The actor shared he had lost 40 pounds since taking the medication.

ABC News chief medical correspondent Dr. Tara Narula explains the findings of a new study on GLP-1 drugs commonly used for weight loss.

The drugs' pricing will be negotiated directly between the government and drug manufacturers.

Just days before leaving the office, President Biden expanded the list of medications to be negotiated by Medicare, including Ozempic and Wegovy.

Dr. Alexandra Sowa, an obesity medicine specialist and author of the new book “The Ozempic Revolution” shares the pros and cons of using GLP-1 medications for weight loss.

ABC News’ medical correspondent Dr. Darien Sutton breaks down the latest medical headlines.

The weight loss drug is now also the first medication for patients with sleep apnea.

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

"GMA" shares an exclusive look inside the lab of the maker of such drugs as Mounjaro and Zepbound to show what it's doing to warn users about the dangers of counterfeit drugs.

Experts say the growing use of weight loss drugs may be helping to reverse obesity trends. ABC News medical contributor Dr. John Brownstein breaks down the latest study.

Experts say the growing use of weight loss drugs may be helping to reverse obesity trends.

The new trend is seeing people take very small doses of medications like Ozempic, Wegovy and Zepbound.

A new study is suggesting that not all weight-loss drugs are created equal.

Study participants treated with Zepbound lost 20% of their body weight.

Eli Lilly says new research shows its medication Zepbound helped patients shed more weight over a shorter period of time than Novo Nordisk’s Wegovy.

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans with Medicare and Medicaid.